Jung-Yun Lee

TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER

Ritu Salani, Shin Nishio, Ana Oaknin, Jean‐Emmanuel Kurtz et autres

us, cn, jp, es, fr, it, ar, de, ca, gb, br, kr, be, nl, at, pl, gr, no (code pays fourni par la source)

TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer

Ritu Salani, Kristina Lindemann, Shin Nishio, Ana Oaknin et autres

us, no, cn, jp, es, fr, it, ar, de, ca, gb, kr, be, nl, at, pl, gr, br, dk (code pays fourni par la source)

Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA nonmutated epithelial ovarian cancer: Results from the randomized phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 study

Matthew A. Powell, David Cibula, Els Van Nieuwenhuysen, Keiichi Fujiwara et autres

us, cz, be, jp, kr, it, il, pl (code pays fourni par la source)

Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A -mutated ovarian clear cell carcinoma or endometrial carcinoma.

Linda Duska, Kalyan Banda, Ana Oaknin, Vincent Ribrag et autres

us, es, fr, kr, gb, it, de (code pays fourni par la source)

Abstract CT249: An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2

Funda Meric-Bernstam, Jung-Yun Lee, Vicky Makker, Ana Oaknin et autres

us, kr, es, gb (code pays fourni par la source)

DDRiver EOC 302: A Randomised Phase 2 Study Of Tuvusertib With Niraparib Or Lartesertib In Patients With Epithelial Ovarian Cancer That Has Progressed On Prior PARP Inhibitor Therapy

Rebecca Kristeleit, Mansoor Raza Mirza, Antonio González-Martı́n, Robert L. Coleman et autres

gb, dk, es, us, kr, de, be (code pays fourni par la source)

An Open-Label, Multicentre, Phase 2 Study Of Trastuzumab Deruxtecan In Patients With HER2-Expressing Solid Tumours: DESTINY-PanTumor02 Part 2

Ana Oaknin, Jung-Yun Lee, Vicky Makker, Do‐Youn Oh et autres

es, kr, us, gb (code pays fourni par la source)

Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study

Ignace Vergote, David Cibula, Matthew A. Powell, Els Van Nieuwenhuysen et autres

be, cz, us, tr, es, jp, hu, kr, it, il, tw, pl (code pays fourni par la source)

Immune Modulation Effect of Administration of Rice Bran Extract with Increased Solubility Fermented by Lentinus edodes UBC-V88 in Cyclophosphamide-Treated Mice Model

Gi-Jung Kim, Ye Ji Jang, Ji‐Yoon Hong, Dae-Weon Kim et autres

kr, us (code pays fourni par la source)

Jeju Citrus (Citrus unshiu) Leaf Extract and Hesperidin Inhibit Small Intestinal α-Glucosidase Activities In Vitro and Postprandial Hyperglycemia in Animal Model

Gi-Jung Kim, Ye Ji Jang, Jae-Won Kim, Seong‐Il Kang et autres

kr, us (code pays fourni par la source)

eVOLVE-Cervical (GOG-3092/ENGOT-cx19/GEICO133-C): A prospective phase III study of volrustomig versus placebo after definitive chemoradiation among women with high-risk, locally advanced cervical cancer

Leslie M. Randall, Xiaohua Wu, Jyoti Mayadev, Munetaka Takekuma et autres

us, cn, jp, br, il, it, kr, es (code pays fourni par la source)

PT003/#255 Clinical outcomes with trastuzumab emtansine or ipatasertib plus paclitaxel for persistent/recurrent rare epithelial ovarian carcinomas: ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed study

David M. Gershenson, Andrés Redondo, Thibault De La Motte Rouge, Rowan Miller et autres